KOR ENG CHN
PRODUCTS
Current Pipeline Status Cell Therapy Product Secretome FECS-SOLUTION Cosmetics Ingredient
Treatment of Parkinson’s Disease
TED-A9

Embryonic Stem Cell-derived A9 Dopaminergic Neuronal Precursor Cells

image
Parkinson’s Disease
A disease that causes problems in motor regulation due to the apoptosis of dopaminergic nuerons present in the substantia nigra of the midbrain
Cause
It is caused by continuous apoptosis of dopaminergic neurons in the substantia nigra of the midbrain (A9).
The cause of apoptosis is not exactly known, except for hereditary reasons.
Symptom
The main symptoms of Parkinson's disease include involuntary tremors of hands and feet, muscle stiffness, lack or slowness in motor skills, and posture instability. It may be accompanied by visual hallucination, auditory hallucination, and insomnia
Basic Research Non-clinical Phase 1 Phase 2 Phase 3 Approval
Nonclinical trial complete scheduled to apply for IND
OUTLINE
Therapy
imageInject into damaged substantia nigra of midbrain imageImprovement of Parkinson's disease
Technology
Embryonic stem cells using TED technology (using DM/SB)
image image
TED
image image
Specific differentiation of A9 dopaminergic neuron precursor cells
DATA
Differentiation to A9 Dopaminergic Neuron Precursor Cells
Immunofluorescence staining

The differentiation into A9 dopaminergic neuron precursor cells (A9-DPC) was confirmed by high expression of En1, FoxA2, and Lmx1A, which are specifically expressed in A9-DPC in the differentiated cells.

image

EN1+/FOXA2+ /LMX1A+ Cell

Confirmation of functions

Dopamine concentration was measurement by inducing differentiation into dopaminergic neurons with TED-A9. As a result of checking dopamine concentrations in differentiation cell cultured medium (Conditioned media), differentiation cell cultured medium stimulated by potassium chloride(KCl), and differentiation cell lysate (Lysate), dopamine was detected in all conditions. Through this, it was confirmed that the differentiated dopaminergic neurons on TED-A9 have functionality.

배경 배경
그래프 그래프
Parkinson’s Disease Improvement
Efficacy test on rats

In the efficacy test on rats, a Parkinson’s disease model was created by using 6-OHDA (6-hydroxydopamine) to kill dopaminergic neurons in one side of their brains. Thereafter, the model was treated with amphetamine to induce asymmetric rotation and the effect of reducing the asymmetric rotation rate due to cell was measured. As a result, the gradual decrease in the number of asymmetric rotations was confirmed over time after TED-A9 transplant.

image image
Efficacy test on marmoset monkeys

In order to reproduce Parkinson's disease in humans, an animal model was prepared with marmoset monkeys using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). In the control group, the severity was maintained whereas in the group with TED-A9 transplant, the severity decreased and recovery to an almost normal state was observed after 200 days.

image image